220 related articles for article (PubMed ID: 35306354)
1. Broadly neutralizing antibodies against HIV-1 and concepts for application.
Gruell H; Schommers P
Curr Opin Virol; 2022 Jun; 54():101211. PubMed ID: 35306354
[TBL] [Abstract][Full Text] [Related]
2. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
Thavarajah JJ; Hønge BL; Wejse CM
Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
[TBL] [Abstract][Full Text] [Related]
3. Broadly Neutralizing Antibodies for HIV-1 Prevention.
Walsh SR; Seaman MS
Front Immunol; 2021; 12():712122. PubMed ID: 34354713
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies for HIV-1 prevention.
Julg B; Barouch DH
Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
[TBL] [Abstract][Full Text] [Related]
5. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
6. Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD; Corey L; Montefiori D
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
[TBL] [Abstract][Full Text] [Related]
7. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
[TBL] [Abstract][Full Text] [Related]
8. Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.
Danesh A; Ren Y; Brad Jones R
Curr Opin HIV AIDS; 2020 Sep; 15(5):316-323. PubMed ID: 32732552
[TBL] [Abstract][Full Text] [Related]
9. Broadly neutralizing antibodies for the treatment and prevention of HIV infection.
Caskey M
Curr Opin HIV AIDS; 2020 Jan; 15(1):49-55. PubMed ID: 31764199
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing antibodies for HIV-1 prevention and therapy.
Julg B; Barouch D
Semin Immunol; 2021 Jan; 51():101475. PubMed ID: 33858765
[TBL] [Abstract][Full Text] [Related]
11. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Awan SF; Happe M; Hofstetter AR; Gama L
Curr Opin HIV AIDS; 2022 Jul; 17(4):247-257. PubMed ID: 35762380
[TBL] [Abstract][Full Text] [Related]
14. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
16. Broadly neutralizing antibodies for HIV treatment and cure approaches.
Frattari GS; Caskey M; Søgaard OS
Curr Opin HIV AIDS; 2023 Jul; 18(4):157-163. PubMed ID: 37144579
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
Mahomed S
Clin Microbiol Rev; 2024 Jun; 37(2):e0015222. PubMed ID: 38687039
[TBL] [Abstract][Full Text] [Related]
18. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic.
Spencer DA; Shapiro MB; Haigwood NL; Hessell AJ
Front Public Health; 2021; 9():690017. PubMed ID: 34123998
[TBL] [Abstract][Full Text] [Related]
19. Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection.
Cohen YZ; Caskey M
Curr Opin HIV AIDS; 2018 Jul; 13(4):366-373. PubMed ID: 29697469
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
Paneerselvam N; Khan A; Lawson BR
Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]